Gene Therapy

Latest News

gene therapy | Image Credit: © RFBSIP - stock.adobe.com
Expanding Broader Patient Access to CGTs

April 30th 2025

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

At 6 months, 81% of wounds showed 50% or more healing vs 16% of 43 matched control wounds treated with standard of care in the VIITAL study. | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa

April 29th 2025

The consensus guidelines aim to provide practical guidance for institutions administering gene therapy in a commercial or trial setting. | Image credit: CrazyJuke - stock.adobe.com
Consensus Guidelines Aim to Optimize DMD Gene Therapy Delivery

April 18th 2025

Real-world data suggest delandistrogene moxeparvovec is well-tolerated and effective in patients with DMD. | Image credit: natali_mis - stock.adobe.com
Real-World Study Suggests DMD Gene Therapy Is Safe, Effective

March 26th 2025

Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy approved for the treatment of DMD. Image credit: natali_mis - stock.adobe.com
Delandistrogene Moxeparvovec Shows Long-Term Impacts at 3 and 5 Years in DMD

March 21st 2025

More News

Male hands showing protection and protection for family security, finances and health ,Insurance management planning ,property and family risk reduction ,Caring and caring for loved ones: © chaylek - stock.adobe.com
June 28th 2023

Researchers Highlight Restrictive Coverage of Gene, Cell Therapies

Jaime Rosenberg
The researchers focused on coverage trends across an array of disease states, including lymphoma, vision loss, and spinal muscular atrophy, finding discrepancies in coverage across 16 states and Medicaid Care Organizations.
FDA Approves Delandistrogene Moxeparvovec, First Gene Therapy to Treat Duchenne Muscular Dystrophy
June 22nd 2023

FDA Approves Delandistrogene Moxeparvovec, First Gene Therapy to Treat Duchenne Muscular Dystrophy

Mary Caffrey
The therapy, to be marketed as Elevidys, is approved for the treatment of ambulatory pediatric patients aged 4 through 5 years with DMD who have a confirmed mutation in the DMD gene.
DNA strand
May 12th 2022

A Look at the Current, Future State of Cell and Gene Therapies in the United States

Gianna Melillo
Experts evaluated the future of cell and gene therapies in the United States and offered insights on potential value-based payment models for these treatments.
Gene Therapies Present Reimbursement Challenges That Have Yet to Be Answered
May 19th 2021

Gene Therapies Present Reimbursement Challenges That Have Yet to Be Answered

Laura Joszt, MA
With more than 3000 gene therapies in development, payers will have to grapple with the challenges of paying for these innovative but expensive therapies.
<1234

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo